The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
2024 · Genome Medicine · 53 citations
https://doi.org/10.1186/s13073-024-01370-z
E
Eduardo García‐Galea
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
57
Papers
213
Citations
7
h-index
6
i10-index
Eduardo García‐Galea is an academic researcher from Hebron University. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Gastrointestinal Tumor Research and Treatment & Colorectal Cancer Treatments and Studies. The author has an h-index of 7, co-authored 49 publications.
ORCID: 0000-0003-4699-0786Papers by this author
worksImproving water quality does not guarantee fish health: Effects of ammonia pollution on the behaviour of wild-caught pre-exposed fish
2021 · PLoS ONE · 47 citations
https://doi.org/10.1371/journal.pone.0243404
88P Real-world data of patients (pts) with BRAF V600E-mutated (mt) metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD–TPI)
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.05.099
P3.14.02 Clinical Implications of BAP1 Status in Pleural Mesothelioma (PM)
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2025.09.972
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat